Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclosporin - Sublimity Therapeutics

Next Previous
Search
Drug Profile

Ciclosporin - Sublimity Therapeutics

Alternative Names: AlloCol; Cyclosporin - Sublimity Therapeutics; Cyclosporine - Sublimity Therapeutics; Cyclosporine A - Sublimity Therapeutics; CyCol; CyCron; CyLow; Oral cyclosporine - Sublimity Therapeutics; ST 0529; STI-0529

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sigmoid Pharma
  • Developer Dr Falk Pharma; Sublimity Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Graft-versus-host disease; Transplant rejection; Ulcerative colitis

Highest Development Phases

  • Phase II Ulcerative colitis
  • No development reported Crohn's disease; Graft-versus-host disease; Psoriasis; Transplant rejection

Most Recent Events

  • 14 Apr 2021 Sublimity Therapeutics and Dr Falk Pharma terminates a phase II trial in Ulcerative colitis in US, Belarus, Bulgaria, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Romania, Russia, Serbia, Spain, Ukraine and the United Kingdom (PO) (NCT03844932)
  • 10 Feb 2021 Phase II development for Ulcerative colitis is still ongoing in USA (PO) (NCT03844932)
  • 18 May 2019 Safety and pharmacokinetics data from a phase I trial in Ulcerative colitis presented at the Digestive Disease Week (DDW-2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top